Efficacy and Safety of Sacubitril/Valsartan Versus Enalapril in the Treatment of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis - PubMed
8 hours ago
- #sacubitril-valsartan
- #meta-analysis
- #heart-failure
- Sacubitril/valsartan significantly reduces all-cause mortality, cardiovascular mortality, and heart failure rehospitalization compared to enalapril in HFrEF patients.
- Hypotension is more frequent with sacubitril/valsartan, but no significant differences were found for hyperkalemia, angioedema, worsening renal function, or LVEF.
- Sacubitril/valsartan is associated with lower NT-proBNP levels and better KCCQ scores than enalapril.
- The study included 10 RCTs and two prospective cohort studies with 11,765 patients.
- Publication bias could not be assessed due to the small number of studies (<10).
- Further research is needed to investigate the long-term safety and effectiveness of sacubitril/valsartan across diverse patient populations.